-
Mashup Score: 0VMX - 10 day(s) ago
Virtual Meeting Experience
Source: vmx.m-anage.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2VMX - 10 day(s) ago
Virtual Meeting Experience
Source: vmx.m-anage.comCategories: General Medicine News, Partners & KOLsTweet-
10/ #Tandem25 #MMsm ASCT category: @LandauHeather @szusmani @GiraltSergio et al. "ASCT without caregiver possible but often requires more inpt time" - maybe not anymore! Nice use of RPM to support home-based transplant monitoring in ongoing trial. https://t.co/8wZ34tEVBg https://t.co/ORvVuP07It
-
-
Mashup Score: 9VMX - 10 day(s) ago
Virtual Meeting Experience
Source: vmx.m-anage.comCategories: General Medicine News, Partners & KOLsTweet-
9/ #Tandem25 #MMsm ASCT category: LoPiccolo #robertvescio et al. Adding scalp cooling cap to split-dose mel: not a single patient developed hair loss afterward! Why such good outcomes vs breast CA? Likely fast mel half-life. So great for patients!! https://t.co/3yKNTnMB78 https://t.co/hObXXqyBCw
-
-
Mashup Score: 10VMX - 10 day(s) ago
Virtual Meeting Experience
Source: vmx.m-anage.comCategories: General Medicine News, Partners & KOLsTweet-
8/ #Tandem25 #MMsm ASCT category: Another great PharmD-track oral by Huang & @fredhutch colleagues inc @AJPortuguese. In propensity-matched model, doublet maintenance beats lenalidomide monotherapy across board. Similar to FORTE, but dara counts here! https://t.co/qMmJiWrnIP https://t.co/JaJK7DBPSP
-
-
Mashup Score: 3VMX - 10 day(s) ago
Virtual Meeting Experience
Source: vmx.m-anage.comCategories: General Medicine News, Partners & KOLsTweet-
7/ #Tandem25 #MMsm ASCT category: Great PharmD track oral by @KarenSweiss! As we debate optimal role of ASCT, worth noting that "MEL 200" is meaningless in terms of what dose pts actually receive. AUC-guided melphalan PK feasible in this ongoing study! https://t.co/1DaeYobR6H https://t.co/GXWqpafJ73
-
-
Mashup Score: 4VMX - 10 day(s) ago
Virtual Meeting Experience
Source: vmx.m-anage.comCategories: General Medicine News, Partners & KOLsTweet-
6/ #Tandem25 #MMsm CAR-T category (COI: mine & @GKaurMD on behalf of Consortium). FDA guidance: avoid driving or operating 🚜 for 8 weeks after CAR-T. Can create hardships for pts & caregivers once home. Is it evidence-based? Our analysis: likely not! https://t.co/R9CAiRt3zI https://t.co/zozBgA5Igl
-
-
Mashup Score: 2VMX - 10 day(s) ago
Virtual Meeting Experience
Source: vmx.m-anage.comCategories: General Medicine News, Partners & KOLsTweet-
5/ #Tandem25 #MMsm CAR-T category: Ferraris @DrFredLocke et al. Very nice Moffitt analysis of PROs after BCMA CAR-T. Why check PROs as SOC? Minorities were much more likely to report meaningful improvements in global pain and fatigue - great to see!! https://t.co/XW1QwvyVsM https://t.co/a2kDflKXcW
-
-
Mashup Score: 3VMX - 10 day(s) ago
Virtual Meeting Experience
Source: vmx.m-anage.comCategories: General Medicine News, Partners & KOLsTweet-
4/ #Tandem25 #MMsm CAR-T category: Lim @YiLinMDPhD @Taxkourel et al. Don't believe me about ALC ⬆️⬆️ driving MNT risk after BCMA CAR-T? Nice Mayo analysis here. Also: 3 pts who got high-dose Cy saw Parkinsonism rapidly resolve. Use Cy early if needed! https://t.co/4HGjjSQuYc https://t.co/Ly3blqnDMK
-
-
Mashup Score: 7VMX - 10 day(s) ago
Virtual Meeting Experience
Source: vmx.m-anage.comCategories: General Medicine News, Partners & KOLsTweet-
3/ #Tandem25 #MMsm CAR-T category: Turner @MileHighMyeloma et al. Preemptive dex whenever ALC > 5.0 after BCMA CAR-T given previous data suggesting higher mortality if ALC ⬆️⬆️. Needs larger validation, but this might reduce MNT risk after cilta-cel! https://t.co/H3QgA8rjy0 https://t.co/AHGyoe3qTv
-
-
Mashup Score: 5VMX - 10 day(s) ago
Virtual Meeting Experience
Source: vmx.m-anage.comCategories: General Medicine News, Partners & KOLsTweet-
2/ #Tandem25 #MMsm CAR-T category: @AlGarfall et al. LBA1 of @BMTCTN 1902, a Ph2 trial of ide-cel for pts with ≤VGPR following ASCT. Like KarMMa-2 C & CARTITUDE-2D, but mandatory len maintenance after. Results embargoed but excited to see them soon! https://t.co/EGiFy495VE https://t.co/2tTghn9ijS
-
11/ #Tandem25 #MMsm ASCT category: Excellent secondary analysis of DETERMINATION by @LaurenMerzMD et al. 73% of Black pts enrolled on this Ph3 trial had Duffy-null - very common inappropriate cause of len dose reduction. Protocols need to be fixed! https://t.co/GOwMnESOmC https://t.co/na9vlQINnw